This trial is active, not recruiting.

Condition prostate cancer
Treatments purified isoflavones, methyl cellulose blend
Phase phase 2
Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborator National Institute on Minority Health and Health Disparities (NIMHD)
Start date December 2009
End date June 2014
Trial size 71 participants
Trial identifier NCT01036321, 1P20MD003375-01, IRB 107980, MCC-15835


The purpose of our study is to recruit and treat 96 men diagnosed with prostate cancer and scheduled for a prostatectomy with a capsule form of either purified isoflavones or placebo for a 3-6 week period to see if we can slow down the rate of prostate cancer growth. A placebo is a pill or something that looks like the medicine that is being studied but has no active medicine in it. We also want to see if taking purified isoflavones is safe and if it reduces lower urinary tract symptoms. In addition, we want to study if purified isoflavones are able to slow the progression of prostate cancer, and the mechanism of action of purified isoflavones. If the safety and the effects of purified isoflavones on slowing down the progression of prostate cancer is shown in our study, this will also be a safe way of treating men who are at high risk of prostate cancer, so that we can prevent prostate cancer in the future.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator)
Primary purpose treatment
(Active Comparator)
Soy-based isoflavone concentrate with methyl cellulose blend filler. 40 mg daily.
purified isoflavones Novasoy 400
Soy-based isoflavone concentrate with methyl cellulose blend filler - Take 2 capsules daily
(Placebo Comparator)
methyl cellulose blend Avicel PH105
Placebo - Take 2 capsules daily

Primary Outcomes

Median Change in Percent Ki-67 From Baseline
time frame: Baseline to post intervention - up to 6 weeks
Number of Toxicity Events by Final Attribution and Treatment Arm
time frame: Up to 6 weeks

Secondary Outcomes

Biomarkers of Disease Progression - Serum PSA
time frame: Up to 6 weeks
Change in Plasma Concentrations of Isoflavone
time frame: Up to 6 weeks
Biomarkers of Disease Progression - Estradiol
time frame: Up to 6 weeks
Biomarkers of Disease Progression - Free Testosterone
time frame: Up to 6 weeks
Biomarkers of Disease Progression - Insulin Like Growth Factor (IGF) Binding Protein -3
time frame: Up to 6 weeks
Biomarkers of Disease Progression - IGF-1
time frame: Up to 6 weeks
Biomarkers of Disease Progression - Sex Hormone-binding Globulin (SHBG)
time frame: Up to 6 weeks
Biomarkers of Disease Progression - Total Testosterone
time frame: Up to 6 weeks

Eligibility Criteria

Male participants from 30 years up to 80 years old.

Inclusion Criteria: - Diagnosis of localized prostate cancer (PCa), based on pathological assessment from biopsy specimens - No prior or current therapy for PCa or history of cancer except non-melanoma skin cancer - Scheduled for prostatectomy between 3- 6 weeks (+/-3 days) after start of study agent - No known history of hepatic or renal disease (LFTs (SGOT/SGPT) > 5.0 x upper limit of normal as evidenced by impairment of baseline laboratory values, Actual creatinine clearance of >60 utilizing the Cockcroft-Gault formula (1976), which employs creatinine measurements and a patient's weight to predict the clearance. The constant is 1.23 for men. - Omnivorous diet - No evidence of prostatitis or urinary tract infection - Able and willing to give written informed consent - Currently not using or willing to discontinue any nutritional supplements that contain soy or soy isoflavones - Not allergic to study supplements - Not on antibiotics - Men who do not consume more than 3 - 4 oz. of soy or soy products per week - Not taking steroid hormones or medications which have known impact on prostatic specific antigen (PSA) - Health status cleared by primary MD or urologist - Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 Exclusion Criteria: - Prior history of prostate cancer; Current or prior history of other malignancies (exceptions include nonmelanoma skin cancer or other cancer with no evidence of tumor recurrence five years after definitive treatment) - History of renal or hepatic disease, including history of hepatitis B, C or delta as evidenced by impairment of baseline laboratory values - Participation in any other investigational study or use of any other investigational agents within 30 days of study entry - History of allergic reactions attributed to soy isoflavones or other compounds of similar chemical or biologic composition to Novasoy 400® or the inactive components present in the purified isoflavone and placebo capsules - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or any psychological, familial, sociological or other concomitant condition that would not allow adequate compliance with the study protocol - Only African American (a person having origins in any of the black racial groups of Africa) and Caucasian (a person having origins in any of the original people of Europe, Middle East, or North Africa) men, as defined by the NIH, will be included in this study. Since this is an investigation targeting men with PCa, women are not eligible for the study.

Additional Information

Official title Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness and Mechanism of Action Between African American and Caucasian Men
Principal investigator Nagi Kumar, Ph.D.
Description Patients will need to take two (2) capsules daily, one with their breakfast and one with their dinner. On the day prior or the day that patients are coming in for their pre-operative surgery blood work, we ask that they take the second dose with lunch, if their appointment is in the afternoon. At the start of the study and at the end of the study (3-6 weeks), patients will undergo interviews, complete questionnaires, and have lab tests to determine if this drug is effective to reduce progression of prostate cancer and is safe to use. Patients will also receive a multivitamin/mineral supplement for the 3-6 weeks that they are on this study and will be required to take one (1) every day. It is required that patients not take any other vitamin/mineral or herbal preparation containing isoflavones and avoid eating or drinking soy products. We anticipate that most patients will be scheduled for a prostatectomy 3-6 weeks (+/- 3 days) from start of study agent. In addition to their first visit, patients will be required to come in the day of the surgery for prostatectomy.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute.